Pharmacological or genetic inhibition of iNOS prevents cachexia-mediated muscle wasting and its associated metabolism defects.

EMBO Molecular Medicine
Jason SadekImed-Eddine Gallouzi

Abstract

Cachexia syndrome develops in patients with diseases such as cancer and sepsis and is characterized by progressive muscle wasting. While iNOS is one of the main effectors of cachexia, its mechanism of action and whether it could be targeted for therapy remains unexplored. Here, we show that iNOS knockout mice and mice treated with the clinically tested iNOS inhibitor GW274150 are protected against muscle wasting in models of both septic and cancer cachexia. We demonstrate that iNOS triggers muscle wasting by disrupting mitochondrial content, morphology, and energy production processes such as the TCA cycle and acylcarnitine transport. Notably, iNOS inhibits oxidative phosphorylation through impairment of complexes II and IV of the electron transport chain and reduces ATP production, leading to energetic stress, activation of AMPK, suppression of mTOR, and, ultimately, muscle atrophy. Importantly, all these effects were reversed by GW274150. Therefore, our data establish how iNOS induces muscle wasting under cachectic conditions and provide a proof of principle for the repurposing of iNOS inhibitors, such as GW274150 for the treatment of cachexia.

References

Sep 8, 1984·British Medical Journal·P W EmeryD Halliday
Sep 29, 2001·Nature Immunology·C Bogdan
Feb 4, 2003·Nature Reviews. Immunology·Bruce Beutler, Ernst Th Rietschel
Mar 13, 2003·Kidney International·Prabal K ChatterjeeChristoph Thiemermann
Mar 26, 2003·Proceedings of the National Academy of Sciences of the United States of America·Junghee LeeRajiv R Ratan
Jul 2, 2003·FEBS Letters·Robert W GilkersonRoderick A Capaldi
Oct 14, 2003·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Volker AdamsRainer Hambrecht
Oct 22, 2003·Archives of Biochemistry and Biophysics·Paul J Thornalley
Oct 22, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Stefan El-GayarChristian Bogdan
Jun 10, 2006·BMC Genomics·Robert A van den BergMariët J van der Werf
Jun 10, 2006·Journal of Inherited Metabolic Disease·Henri Brunengraber, Charles R Roe
Nov 30, 2006·Journal of Cellular Biochemistry·Bingwen Jin, Yi-Ping Li
Mar 31, 2007·Molecular and Cellular Biochemistry·Laura NanettiLaura Mazzanti
Aug 2, 2007·Nature Reviews. Drug Discovery·Csaba SzabóRafael Radi
May 12, 2009·Nucleic Acids Research·Jianguo XiaDavid S Wishart
May 28, 2009·American Journal of Physiology. Endocrinology and Metabolism·Sonia RamamoorthyMartina Buck
Aug 12, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Aminah JatoiCharles L Loprinzi
Jan 7, 2010·Journal of Cancer Survivorship : Research and Practice·Rebecca M SpeckKathryn H Schmitz
Oct 27, 2010·Cephalalgia : an International Journal of Headache·Hans Olav HøivikMartin W Lunnon
Dec 9, 2010·British Journal of Cancer·V KostourouS P Robinson
Feb 8, 2011·The Lancet Oncology·Kenneth FearonVickie E Baracos
Jun 3, 2011·Current Protocols in Bioinformatics·Jianguo Xia, David S Wishart
Oct 6, 2011·British Journal of Cancer·R A MurphyM Mourtzakis
Oct 15, 2011·Expert Opinion on Biological Therapy·Trevor J BaylissJames R Rigas
Dec 14, 2011·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Rosemary A SchuhEspen E Spangenburg
Mar 23, 2012·Nature Reviews. Molecular Cell Biology·D Grahame HardieSimon A Hawley
Apr 6, 2012·Journal of Cachexia, Sarcopenia and Muscle·Melissa J PuppaJames A Carson
May 4, 2012·Nucleic Acids Research·Jianguo XiaDavid S Wishart
May 9, 2012·Journal of Cachexia, Sarcopenia and Muscle·Josep M ArgilésFabio Penna
Jun 14, 2012·Nature Communications·Sergio Di MarcoImed Eddine Gallouzi
Jul 4, 2012·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·J M ArgilésS Busquets
Jul 17, 2012·Cell Metabolism·Kenneth C H FearonDenis C Guttridge
Aug 30, 2012·Nature Methods·Caroline A SchneiderKevin W Eliceiri
Sep 19, 2012·Mediators of Inflammation·Jan VítečekLukáš Kubala

❮ Previous
Next ❯

Citations

Aug 25, 2021·Experimental Cell Research·Paige C Arneson-Wissink, Jason D Doles

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cachexia & Brown Fat

Cachexia is a condition associated with progressive weight loss due to severe illness. In cancer patients, it is proposed to occur as a result of tumor-induced energy wasting. Several proteins have been implicated in browning and depletion of white adipose tissue. Here is the latest research on cachexia and brown fat.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.